Literature DB >> 12709359

Lamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V-->I) of the reverse transcriptase.

Carlos Toro, Berta Rodés, Carmen de Mendoza, Vincent Soriano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12709359      PMCID： PMC153342          DOI： 10.1128/AAC.47.5.1774-1775.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs.

Authors:  A Machuca; V Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2000-06-01       Impact factor: 3.731

Review 2.  Mechanisms of resistance to antiretroviral drugs--clinical implications.

Authors:  Carmen de Mendoza; Oscar Gallego; Vincent Soriano
Journal:  AIDS Rev       Date:  2002 Apr-Jun       Impact factor: 2.500

3.  A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.

Authors:  K Hertogs; S Bloor; V De Vroey; C van Den Eynde; P Dehertogh; A van Cauwenberge; M Stürmer; T Alcorn; S Wegner; M van Houtte; V Miller; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.

Authors:  J G García-Lerma; S Nidtha; W Heneine
Journal:  J Infect Dis       Date:  2001-07-25       Impact factor: 5.226

5.  Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors.

Authors:  S H Qari; S Magre; J G García-Lerma; A I Hussain; Y Takeuchi; C Patience; R A Weiss; W Heneine
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy.

Authors:  G P Taylor; S E Hall; S Navarrete; C A Michie; R Davis; A D Witkover; M Rossor; M A Nowak; P Rudge; E Matutes; C R Bangham; J N Weber
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  The effect of antiretroviral therapy on HTLV infection.

Authors:  A Machuca; B Rodés; V Soriano
Journal:  Virus Res       Date:  2001-10-30       Impact factor: 3.303

8.  Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine.

Authors:  E K Halvas; E S Svarovskaia; E O Freed; V K Pathak
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

9.  Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro.

Authors:  Emanuela Balestrieri; Giancarlo Forte; Claudia Matteucci; Antonio Mastino; Beatrice Macchi
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191
  9 in total
  7 in total

Review 1.  Adult T cell leukemia lymphoma.

Authors:  Lee Ratner
Journal:  Front Biosci       Date:  2004-09-01

2.  Effect of phosphonated carbocyclic 2'-oxa-3'-aza-nucleoside on human T-cell leukemia virus type 1 infection in vitro.

Authors:  Emanuela Balestrieri; Claudia Matteucci; Arianna Ascolani; Anna Piperno; Roberto Romeo; Giovanni Romeo; Ugo Chiacchio; Antonio Mastino; Beatrice Macchi
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

3.  Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-associated myelopathy to reverse transcriptase inhibitors.

Authors:  Beatrice Macchi; Emanuela Balestrieri; Arianna Ascolani; Silva Hilburn; Fabiola Martin; Antonio Mastino; Graham P Taylor
Journal:  Viruses       Date:  2011-05-05       Impact factor: 5.048

4.  Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial.

Authors:  Graham P Taylor; Peter Goon; Yoshitaka Furukawa; Hannah Green; Anna Barfield; Angelina Mosley; Hirohisa Nose; Abdel Babiker; Peter Rudge; Koichiro Usuku; Mitsuhiro Osame; Charles R M Bangham; Jonathan N Weber
Journal:  Retrovirology       Date:  2006-09-19       Impact factor: 4.602

Review 5.  Antiretroviral Therapy in HTLV-1 Infection: An Updated Overview.

Authors:  Francesca Marino-Merlo; Emanuela Balestrieri; Claudia Matteucci; Antonio Mastino; Sandro Grelli; Beatrice Macchi
Journal:  Pathogens       Date:  2020-05-01

Review 6.  HTLV-1 Transmission and HIV Pre-exposure Prophylaxis: A Scoping Review.

Authors:  Daniel Bradshaw; Graham Philip Taylor
Journal:  Front Med (Lausanne)       Date:  2022-04-29

Review 7.  Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma.

Authors:  Francesca Marino-Merlo; Antonio Mastino; Sandro Grelli; Olivier Hermine; Ali Bazarbachi; Beatrice Macchi
Journal:  Front Microbiol       Date:  2018-05-09       Impact factor: 5.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.